12:00 AM
Feb 11, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Soluble Ferric Pyrophosphate: Phase II data

Top-line data from the double-blind, placebo-controlled, U.S. Phase II PRIME trial in 103 hemodialysis patients with iron deficiency anemia showed that 11 µg/dL SFP delivered via dialysate met the primary endpoint of reducing ESA dose required to maintain target hemoglobin levels from baseline to week 36 vs. conventional dialysate without iron. Specifically, patients receiving SFP delivered via dialysate required 37.1% less usage of ESAs vs....

Read the full 305 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >